Hebrew University' Yissum and
Israeli Biotech Clearmind Medicine's Psychedelic-Derived Obesity
Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at
Isranalytica 2023
Isranalytica 2023,
the Annual meeting of the Israel Analytical Chemical Society,
provided Clearmind with the opportunity to garner visibility for
its drug candidate MEAI from attendees at one of the largest annual
analytical chemistry conferences in the world
Tel Aviv, Israel / Vancouver,
Canada, Jan. 23, 2023 -- InvestorsHub NewsWire -- Clearmind
Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) ("Clearmind" or the "company"), a
biotech company focused on discovery and development of novel
psychedelic-derived therapeutics to solve major under-treated
health problems, today announced that Professor Joseph Tam, D.M.D.,
Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest
results at Isranalytica
2023.
The presentation, titled
"The Psychoactive
Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its
Metabolic Complications," included data from recently announced
pre-clinical results demonstrating efficacy of Clearmind's drug
candidate MEAI for treating obesity and metabolic
syndrome.
Isranalytica 2023, the Annual
Meeting of the Israel Analytical Chemical Society, ranks as one of
the world's largest annual analytical chemistry conferences.
Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and
Metabolism Laboratory, and he is an Associate Professor of
Pharmacology at the Hebrew University's Institute for Drug
Research. Along with Dr. Saja Baraghithy, Ph.D., he led the
pre-clinical trial as part of Clearmind's robust collaboration with
the Hebrew University and its technology transfer
company Yissum.
"We are honored that our research
partner, Professor Joseph Tam, chose to present the promising
results of our MEAI-based treatment for obesity to professionals
and medical peers," said Clearmind's CEO Dr. Adi Zuloff-Shani. "One
of our targets is to expand the awareness to our unique treatments
among the scientific and medical community, as a wide network will
facilitate our future clinical programs."
About Clearmind Medicine
Inc.
Clearmind is a psychedelic
pharmaceutical biotech company focused on the discovery and
development of novel psychedelic-derived therapeutics to solve
widespread and underserved health problems, including alcohol use
disorder. Its primary objective is to research and develop
psychedelic-based compounds and attempt to commercialize them as
regulated medicines, foods or supplements.
The company's intellectual
portfolio currently consists of seven patent families. The company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its
portfolio.
Shares of Clearmind are listed for
trading on Nasdaq and the Canadian Securities Exchange under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol
"CWY".
For further information
visit: https://www.clearmindmedicine.com or
contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604)
260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
About Yissum
Yissum is the technology transfer
company of The Hebrew University of Jerusalem. Founded in 1964, it
serves as a bridge between cutting-edge academic research and a
global community of entrepreneurs, investors, and industry.
Yissum's mission is to benefit society by converting extraordinary
innovations and transformational technologies into commercial
solutions that address our most urgent global challenges. Yissum
has registered over 11,000 patents globally; licensed over 1,140
technologies and has spun out more than 200 companies. Yissum's
business partners span the globe and include companies such as
Boston Scientific, ICL, Intel, Johnson & Johnson, Merck,
Novartis and many more. For further information please
visit www.yissum.co.il
FORWARD-LOOKING
STATEMENTS:
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act and other securities laws. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. For
example, the Company is using forward-looking statements when it
discusses the results of preclinical trials, conducting future
trials, the results of future projects, the submission of patent
applications and that psychedelic based treatments hold potential
to address and provide dedicated solutions for various mental
health conditions. Forward-looking statements are not historical
facts, and are based upon management's current expectations,
beliefs and projections, many of which, by their nature, are
inherently uncertain. Such expectations, beliefs and projections
are expressed in good faith. However, there can be no assurance
that management's expectations, beliefs and projections will be
achieved, and actual results may differ materially from what is
expressed in or indicated by the forward-looking statements.
Forward-looking statements are subject to risks and uncertainties
that could cause actual performance or results to differ materially
from those expressed in the forward-looking statements. For a more
detailed description of the risks and uncertainties affecting the
Company, reference is made to the Company's reports filed from time
to time with the Securities and Exchange Commission ("SEC"),
including, but not limited to, the risks detailed in the Company's
final prospectus (registration No. 333-265900) filed with the SEC
on November 16, 2022. Forward-looking statements speak only as of
the date the statements are made. The Company assumes no obligation
to update forward-looking statements to reflect actual results,
subsequent events or circumstances, changes in assumptions or
changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.